Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diot, E.
Right arrow Articles by Lemarié, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diot, E.
Right arrow Articles by Lemarié, E.
(Chest. 1999;116:715-720.)
© 1999 American College of Chest Physicians

Is Anti-Topoisomerase I a Serum Marker of Pulmonary Involvement in Systemic Sclerosis?*

Elisabeth Diot, MD; Bruno Giraudeau, PhD; Patrice Diot, MD, PhD; Danielle Degenne, PharmD; Laurence Ritz, MD; Jean-Louis Guilmot, MD and Etienne Lemarié, MD

* From the Groupe de Recherche Epithélium Respiratoire et Inflammation (Drs. E. Diot, Ritz, and Guilmot), Services de Médecine Interne B, Immunologie (Dr. Degenne), et Pneumologie (Drs. P. Diot and Lemarié), CHU Bretonneau, Tours, France; and Centre de Recherche Clinique (Dr. Giraudeau), Faculté de Médecine, Tours, France.

Correspondence to: Patrice Diot, MD, PhD, Service de Pneumologie, CHU Bretonneau, 2 bis Boulevard Tonnellé, 37044 Tours Cedex, France; e-mail: diot{at}med.univ-tours.fr

Study objective: To determine the value of the level of anti-topoisomerase I (anti-topo I) to evaluate lung involvement defined by abnormal high-resolution computed tomography (HRCT) score and pulmonary function tests (PFTs) in systemic sclerosis (SS).

Patients: Forty-eight patients with SS, 20 with lung involvement and 28 with no lung involvement.

Design: PFT measurement, HRCT scoring of lung involvement, and anti-topo I assay by enzyme-linked immunosorbent assay. Normal anti-topo I level was defined as < 30.

Results: There was a significant association between cutaneous extent and anti-topo I level (6.5% of patients with limited cutaneous scleroderma had abnormal anti-topo I levels vs 70.6% of patients with diffuse cutaneous scleroderma, p = 0.0001). In patients with diffuse cutaneous scleroderma, pulmonary involvement was associated with a higher percentage of abnormal anti-topo I level: 91.7% vs 20% (p = 0.010). In patients with diffuse cutaneous scleroderma, a significant association was found between the class of anti-topo I level and total lung capacity (median, 69 in patients with abnormal anti-topo I level vs 87 in patients with normal anti-topo I level, p = 0.010), between the class of anti-topo I level and HRCT score (median, 12 in patients with abnormal anti-topo I level vs 5 in patients with normal anti-topo I level, p = 0.05).

Conclusion: Anti-topo I can be considered as a marker of lung involvement in patients with diffuse cutaneous scleroderma.

Key Words: anti-topoisomerase • pulmonary involvement • systemic sclerosis




This article has been cited by other articles:


Home page
 J. Immunol.Home page
X. Zhou, F. K. Tan, M. Xiong, D. M. Milewicz, C. A. Feghali, M. J. Fritzler, J. D. Reveille, and F. C. Arnett
Systemic Sclerosis (Scleroderma): Specific Autoantigen Genes Are Selectively Overexpressed in Scleroderma Fibroblasts
J. Immunol., December 15, 2001; 167(12): 7126 - 7133.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.